Skip to main content

East Surrey

Information from Meds Management:

Dear Nick Cahm,

Thank you for your  enquiry on ESCCG’s Freestyle Libre policy.

The CCG's  current decision remains the same until the 1st April 2019 (see ESCCG updated position statement from November 2018: https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/5674).

East Surrey CCG are in the process of implementing the national arrangements as described by NHS England, in readiness for the 1st April 2019. An update to the position statement and prescribing information will be made available on the Surrey PAD from this date.

I hope this helps with your query.

Here is the information from the Surrey PAD (plenty of additional information on the website linked above):

INTERIM HOLDING STATEMENT:

The APC has recommended prescribing of flash glucose monitoring system (FGS) in line with guidance from NHS England

It was given a BLUE traffic light status.

Commencement must be within a diabetes specialist led clinic.  At least 1 month supply of sensors must be provided  (current exception is a local agreement with Frimley Healthcare NHS Foundation Trust which is a minimum of 2 weeks supply) by diabetes specialist teams before the patients primary care prescriber is asked to accept clinical responsibility for prescribing flash glucose sensors for individual patients.

Patients should not be referred specifically for the initiation of FGS. Eligibility is expected to be assessed during routine consultations with specialist as part of the patient's annual diabetes review or a review that takes place as a result of other changes in their diabetic needs

The APC policy statement is being written but this interim statement will provide some clarity for patients and prescribers whilst the details are being finalised


New patients

Will be treated as per the NHS England guidance issued on 7th March 2019. The Diabetes specialist service will consider treatment initiation at the patient’s next scheduled diabetes appointment. Patients should not be referred into NHS services just for consideration of FGS.

Patients initiated on FreeStyle Libre under RMOC guidance by NHS specialist diabetes service

Patients will continue to be treated as per the initiation criteria as long as there has been observable improvements in their diabetes.

Type 1 diabetes patients purchasing FreeStyle Libre independently or through a private arrangement


If the patient meets NHS England guidance for initiation of FGS, the patient can be referred into the NHS Type 1 diabetes service. Do not make an urgent referral. Patients should continue to self-fund until the NHS diabetes specialist service has considered initiation in line with NHS England guidance.

Comments

Popular posts from this blog

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d